Summary Isoforms of the transmembrane glycoprotein CD44 have been implicated in tumour cell adhesion, tumour differentiation and metastatic spread in various human malignancies. We investigated the expression of CD44 isoforms containing variant exons v3, v5, v6 and v7-8 
Endometrial cancer is the most common neoplasm of the female genital tract. In recent years the incidence of endometrial cancer has shown a steady increase (Gallup et al, 1984) . A closer followup of post-menstrual bleedings and a greater awareness of women towards the disease has led to an increasing number of women diagnosed with early-stage endometrial cancer. New prognostic indicators could be helpful in defining high-risk collectives within this group of patients who generally enjoy an excellent prognosis.
The transmembrane receptor protein CD44 belongs to the family of adhesion molecules, which are involved in cell-cell and cell-matrix interactions. CD44 mediates lymphocyte functions, such as cell activation, motility, division, adhesion to extracellular matrix and adhesion to stromal cells (Stamenkovic et al, 1991) . CD44 proteins are encoded by a gene located on chromosome 11. By modifications of pre-messenger RNA, i.e. alternative splicing, numerous isoforms of the CD44 protein are produced (CD44 isoforms CD44vl-CD44v1O) (Tanabe et al, 1994) .
Expression of CD44 isoforms has been shown to be associated with metastasis and poor prognosis in colorectal cancer, gastrointestinal lymphoma, non-Hodgkin's lymphoma, thyroid, cervical and vulvar cancer (Jalkanen et al, 1991; Joensuu et al, 1993a; Wielenga et al, 1993; Figge et al, 1994; Kainz et al, 1995; Tempfer et al, 1996) .
The CD44 standard molecule as well as CD44 isoforms, e.g. (Fujita et al, 1994) .
The aim of our study was to evaluate whether CD44 isoform expression is a prognostic factor in endometrial cancer. CD44 isoform expression could eventually be used as a means to identify patients who would profit from adjuvant therapy. To address these questions, we examined the expression of CD44 isoforms CD44v3, CD44v5, CD44v6 and CD44v7-8 in tumour samples of 156 patients with surgically treated endometrial cancer.
MATERIALS AND METHODS
We investigated a randomly selected sample of 156 paraffinembedded tumour specimens of surgically treated endometrial cancer. The median age of the patients was 59 years (range 48-71 years). Patients operated upon from 1976 to 1991 underwent hysterectomy and bilateral salpingo-oophorectomy. Because of the study period, lymphadenectomy, as recommended by Malviya and colleagues and Morrow and colleagues, was not performed on a regular basis (Malviya et al, 1989; Morrow et al, 1991) . Therefore the lymph node status was not included in further analysis. The median follow-up time was 82.6 months (range 39-110 months).
During the observation period, 23 patients showed recurrence of disease. Nineteen patients died of the disease.
Endometrioid-type adenocarcinomas, adenosquamous carcinomas, clear cell carcinomas and undifferentiated adenocarcinomas were found in 113, 25, eight and ten cases respectively. All 1137 cases were reviewed by an experienced pathologist with regard to tumour stage and histological grading. Histological staging was performed according to the current UICC classification (Hermanek et al, 1992) .
We also investigated 45 specimens of normal endometrial tissue, 19 of them being in the proliferative phase and 26 in the secretory phase of the menstrual cycle. The endometrial specimens were taken from randomly selected tissue samples of patients with benign conditions, e.g. myoma uteri.
Immunohistochemistry
Immunohistochemical procedures were performed as described previously . We interpreted widespread staining as positive, focal staining (< 10% of the tumour cells) as negative.
Statistics
Chi-square test was used when appropriate. Survival probabilities were calculated by the product limit method of Kaplan and Meier. Differences between groups were tested using the log-rank test. Cox proportional hazards regression model was used to assess the independence of different prognostic factors. In multivariate analysis, the different CD44 isoforms were tested for their independent effect, adjusted for histological grading. Kendall-Tau correlation coefficient was used to assess the correlation between the expression of different CD44 isoforms. The significance level assumed was alpha = 0.05. In the univariate analysis, the expression of CD44v3 (log-rank test, P = 0.5), CD44v5 (log-rank test, P = 0.3) and CD44v7-8 (logrank test, P = 0.4) did not predict patient survival. Although the expression of CD44v6 showed an association with shortened overall survival (Figure 1 ), univariate analysis demonstrated that this association was not statistically significant (log-rank test, P = 0.06). Multivariate analysis correcting for the confounding variable histological grading revealed CD44v6 not to be an independent prognostic factor of overall survival (log-rank test, P = 0.06, Table 1 ).
RESULTS
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DISCUSSION
The expression of CD44 variant isoforms has been shown to be associated with poor prognosis in a wide variety of human malignancies, e.g. colorectal cancer, gastrointestinal lymphoma, nonHodgkin's lymphoma and cervical cancer (Jalkanen et al, 1991; Joensuu et al, 1993a; Wielenga et al, 1993; Kainz et al, 1995) . However, CD44 has been shown to be down-regulated after malignant transformation of certain cell types (Salmi et al, 1993) and the prognostic value of CD44 isoform expression in ovarian and breast cancers is discussed controversially (Joensuu et al, 1993b; Kaufmann et al, 1995; Sliutz et al, 1995; Uhl-Steidl et al, 1995) . It may be speculated that the role of CD44 as a metastasis mediator in these hormonally regulated malignancies is impaired by hormonal interference with biological properties of CD44. On the other hand, CD44 expression is not correlated with hormonal phenotypes in neuroendocrine tumours and has been shown to be independent of oestrogen and progesterone receptor status in breast cancer (Komminoth et al, 1996; Charpin et al, 1997) .
In the present study, we found CD44 isoforms CD44v3, CD44v5, CD44v6 and CD44v7-8 to be expressed in endometrial cancer in relatively low amounts, ranging from 13% to 29%. The CD44 in endometrial cancer 1139 immunohistochemical approach of detecting CD44 overexpression must be viewed with care because of possible modifications of cell surface expression as a result of embedding procedures. However, in recent studies, an excellent correlation between the detection of CD44 isoforms by immunohistochemistry and reverse transcription polymerase chain reaction has been reported (Dall et al, 1995) .
Yaegashi and colleagues have shown that the expression of CD44 isoforms in normal endometrial tissue is restricted to the secretory phase of the menstrual cycle (Yaegashi et al, 1995) . This is confirmed by our results pointing to a functional role of CD44 in normal endometrial tissue.
A review of the literature shows that no data concerning the prognostic value of CD44 isoform expression in endometrial cancer have been reported. In the present study, we found that the expression of CD44 isoforms CD44v3, CD44v5 and CD44v7-8 is not associated with established prognostic parameters and is not predictive of the patient's outcome. This is in accordance with findings reported by Fujita and colleagues, who found no correlation between CD44 isoform expression and clinicopathological risk factors in a series of 47 endometrial carcinomas (Fujita et al, 1994) .
We found CD44v6 to be expressed in 22% of endometrial carcinomas. Although the expression of CD44v6 showed an association with shortened overall survival, univariate analysis (log-rank test, P = 0.06) and multivariate analysis correcting for the confounding variable histological grading (log-rank test, P = 0.06) revealed CD44v6 not to be a prognostic factor in endometrial cancer.
In summary, our data indicate that the expression of CD44 isoforms, while obviously playing a role in the functional changes of normal endometrium, is not an adverse predictive factor in endometrial cancer.
